For Immunotherapy in TNBC, Nab-paclitaxel Is a Must For Immunotherapy in TNBC, Nab-paclitaxel Is a Must
Why are results so different between IMpassion130 and IMpassion131? There is no clear answer, says Dr Kathy Miller.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

' Paradigm Shift' in Gastric Junction Cancers With Nivolumab'Paradigm Shift' in Gastric Junction Cancers With Nivolumab
Nivolumab immunotherapy could soon be used in the first-line in gastric or gastroesophageal junction cancers, improving the traditionally poor outcomes seen with chemotherapy, show latest trials.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 23, 2020 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

A Glimmer of Hope for Immunotherapy in SCLC? A Glimmer of Hope for Immunotherapy in SCLC?
While combination immunotherapy did not show a survival benefit after chemoradiotherapy in small cell lung cancer, longer follow-up and biomarker analysis may reveal some gains, suggests trial data.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Scientists identify dozens of genes allowing cancer cells to evade the immune system
(University of Toronto) Cancer immunotherapy can be extremely successful but so far has only worked in a fraction of patients and tumour types. To make it more widely available, more knowledge is needed about the genes involved in the interaction between cancer and immune cells. In the most comprehensive study to date, Toronto scientists have mapped 182 genes that make cancer cells more susceptible or resistant to T cell killing that could be harnessed to boost immunotherapy success. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 23, 2020 Category: Cancer & Oncology Source Type: news

Novel dual CAR T cell immunotherapy holds promise for targeting the HIV reservoir
(University of Pennsylvania School of Medicine) A recent study published in the journal Nature Medicine, led by researchers James Riley, PhD, a professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania, and Todd Allen, PhD, a professor of Medicine at Harvard Medical School and Group Leader at the Ragon Institute of MGH, MIT and Harvard, describes a new Dual CAR T cell immunotherapy that can help fight HIV infection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 23, 2020 Category: International Medicine & Public Health Source Type: news

Immunotherapy Drug Boosts Survival With Bladder Cancer
Title: Immunotherapy Drug Boosts Survival With Bladder CancerCategory: Health NewsCreated: 9/21/2020 12:00:00 AMLast Editorial Review: 9/22/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 22, 2020 Category: Cancer & Oncology Source Type: news

BioCanRx invests $10 million in promising new cancer immunotherapy research and biomanufacturing
(BioCanRx - Canada's Immunotherapy Network) BioCanRx, Canada's Immunotherapy Network, announces funding of $10M for 14 cancer immunotherapy research projects and eight core and biomanufacturing facilities. In addition to BioCanRx's investment, partner contributions of $16.5M increase the investment in Canadian translational cancer immunotherapy research and manufacturing to $26.5M. Projects include cross-disciplinary teams working on new, rational combination approaches and unique cell, vaccine/virus-based and antibody immunotherapies. Investments in Canada's biomanufacturing capacity and point-of-care cell manufacturing w...
Source: EurekAlert! - Social and Behavioral Science - September 22, 2020 Category: International Medicine & Public Health Source Type: news

Advantages of Oncolytic Viruses as Immunotherapies to be Discussed by...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb September 22, 2020)Read the full story at https://www.prweb.com/releases/advantages_of_oncolytic_viruses_as_immunotherapies_to_be_discussed_by_catalent_gene_therapy_expert_at_world_vaccine_congress/prweb17410197.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 22, 2020 Category: Pharmaceuticals Source Type: news

As nation mourns Ruth Bader Ginsburg, a look at advances in pancreatic cancer treatment
Ruth Bader Ginsburg, who served on the Supreme Court since 1993, died of pancreatic cancer Sept. 18.Ginsburg battled cancer several times throughout her life. She was treated for colon cancer in 1999, underwent surgery for pancreatic cancer in 2009 and had cancerous lesions removed from her lung in 2018. Ginsburg received chemotherapy for a recurrence of pancreatic cancer in 2019.Pancreatic cancer is the third leading cause of cancer-related death in the United States. A 6-inch-long gland in the abdomen, the pancreas makes digestive enzymes and hormones, such as insulin, that control blood sugar.No screening test exists fo...
Source: UCLA Newsroom: Health Sciences - September 22, 2020 Category: Universities & Medical Training Source Type: news

Immunotherapy Drug Boosts Survival With Bladder Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 21, 2020 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Pharmacy, Research, News, Source Type: news

Lenvatinib Combo May Offer Hope After Immunotherapy in Melanoma Lenvatinib Combo May Offer Hope After Immunotherapy in Melanoma
The combination of lenvatinib and pembrolizumab may extend by more than 1 year the lives of patients with advanced melanoma who progress after immunotherapy, show'important'trial results.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Orthostatic vital signs algorithm: decreasing falls in patients undergoing blood and marrow transplantation or treatment with cellular immunotherapy - Grady L, Klein J, Patterson AE, Pompos C, Reich RR, Mason TM.
BACKGROUND: Falls experienced by patients undergoing blood and marrow transplantation or treatment with cellular immunotherapy (BMT-CI) may result in injury or death. An algorithm was developed using the patient fall circumstances identified in a chart ana... (Source: SafetyLit)
Source: SafetyLit - September 21, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Immunotherapy Drug Avelumab Boosts Survival With Bladder Cancer
MONDAY, Sept. 21, 2020 -- An immunotherapy drug significantly improved survival in patients with the most common type of bladder cancer, according to a new study. About 550,000 new cases of bladder cancer are diagnosed worldwide each year, making... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 21, 2020 Category: General Medicine Source Type: news

Penn researchers discover potential cause of immunotherapy-related neurotoxicity
(University of Pennsylvania School of Medicine) New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB). This discovery may potentially be the cause for neurotoxicity in patients undergoing CD19 directed CAR T cell immunotherapy, according to the research team led by Avery Posey, PhD, an assistant professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2020 Category: Cancer & Oncology Source Type: news

Immunotherapy is beneficial in gastric and oesophageal cancers, studies show
(European Society for Medical Oncology) New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2020 Category: Cancer & Oncology Source Type: news

Regulatory T cells could lead to new immunotherapies aimed at treating multiple sclerosis
(University of California - Irvine) In a new University of California, Irvine-led study, researchers have discovered how regulatory T cells (Treg) are instrumental in limiting the damage caused to the spinal cord in diseases like multiple sclerosis (MS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2020 Category: International Medicine & Public Health Source Type: news

Trial finds benefit of immunotherapy-chemotherapy combination in early-stage triple-negative breast cancer
Adding an immunotherapy agent to a three-drug chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer will recede to undetectable levels (Source: BWH News)
Source: BWH News - September 20, 2020 Category: Hospital Management Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news

Immunotherapy combination improves outcomes in advanced kidney cancer
(Dana-Farber Cancer Institute) An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 19, 2020 Category: Cancer & Oncology Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Immunotherapy improves survival in advanced bladder cancer patients
(Queen Mary University of London) An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2020 Category: International Medicine & Public Health Source Type: news

Increasing the effectiveness of cancer treatments: Anti-PD-L1 immunotherapy
(Tokyo Medical and Dental University) Researh teams of Tokyo Medical and Dental University (TMDU) and Harvard Medical School (HMS) have uncovered how to increase the efficacy of anti-PD-L1 immunotherapy. Using a combination of molecular, biochemical, and bioinformatics approaches, they discovered that the nuclear localization of PD-L1 is controlled by acetylation at a single, specific, Lys site. In the nucleus, PD-L1 controls the expression of immune related genes. Therefore, targeting PD-L1 nuclear localization could enhance the efficacy of PD-1/PD-L1 blockade based immunotherapies. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 18, 2020 Category: Biology Source Type: news

Increasing the effectiveness of immunotherapy against skin cancer
(University of Bern) Researchers at the University of Bern have discovered a mechanism in the body's own immune system which is responsible for the maturation and activation of immune cells. In the fight against skin cancer, the results have the potential to help immunotherapies succeed, even in patients for whom they have so far been ineffective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 18, 2020 Category: Cancer & Oncology Source Type: news

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
In this study, we isolated three bacterial species—Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species—that significantly enhanced efficacy of immune checkpoint inhibitors in four mouse models of cancer. We found that intestinal B. pseudolongum modulated enhanced immunotherapy response through production of the metabolite inosine. Decreased gut barrier function induced by immunotherapy increased systemic translocation of inosine and activated antitumor T cells. The effect of inosine was dependent on T cell expression of the adenosine A2A receptor and required costimulation. Collectively...
Source: ScienceNOW - September 17, 2020 Category: Science Authors: Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., McCoy, K. D. Tags: Immunology, Medicine, Diseases reports Source Type: news

Timing of Radiation Plus Immunotherapy Could Be Key to Antitumor Response in Kidney Cancer Timing of Radiation Plus Immunotherapy Could Be Key to Antitumor Response in Kidney Cancer
Appropriate timing of radiation and immunotherapy likely will improve the antitumor response in kidney cancer, a high-throughput analysis suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 16, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Immune 'cloaking' in cancer cells and implications for immunotherapy
(Queen Mary University of London) Researchers at Queen Mary University of London, The Institute of Cancer Research, London, and the Moffitt Cancer Centre have created a mathematical model that can determine the impact of the immune system on tumour evolution. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 16, 2020 Category: Cancer & Oncology Source Type: news

Stop Livin to make lymphoma cells stop living
(University of Tsukuba) Researchers at the University of Tsukuba have shown that the protein Livin, an inhibitor of apoptosis or programmed cell death, mediates resistance to immunotherapy in some lymphoma variants. Therapeutically targeting Livin with IAP inhibitors or BET inhibitors may provide a practical strategy for patients with Livin-positive and other refractory B-cell lymphomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 16, 2020 Category: Cancer & Oncology Source Type: news

Why investors cannot resist immunotherapy
Research into ways of tweaking the body’s cellular defences has huge clinical potential (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 15, 2020 Category: Pharmaceuticals Source Type: news

UofL lands $11.5M grant to create new cancer center
The university will deepen its work in cancer immunotherapies and will receive a "center of excellence" designation from the federal government. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 14, 2020 Category: Pharmaceuticals Authors: Chris Larson Source Type: news

The March of Immunotherapy Continues at ESMO 2020 The March of Immunotherapy Continues at ESMO 2020
At the ESMO 2020 Congress, there will be no shortage of advances in cancer care on display, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

UofL receives $11.5 million to advance cancer immunotherapies
(University of Louisville) The University of Louisville has received a grant of $11.5 million from the National Institute of General Medical Sciences to establish the Center for Cancer Immunology and Immunotherapy. The new center will develop and improve strategies that use the immune response to fight cancer. The five-year grant funds the CCII as an NIH-designated Center of Biomedical Research Excellence to support young investigators and develop additional basic, translational and clinical research at the UofL Health - James Graham Brown Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2020 Category: Cancer & Oncology Source Type: news

Wistar appoints Ami Patel as Caspar Wistar Fellow
(The Wistar Institute) The Wistar Institute announces the appointment of Ami Patel, Ph.D., as a Caspar Wistar Fellow in the Vaccine and Immunotherapy Center. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 14, 2020 Category: Infectious Diseases Source Type: news

Fighting breast cancer with nanotech, immunotherapy  
(Case Western Reserve University) Scientists led by a   researcher at the Case Western Reserve University   School of Medicine   are making strides to fight deadly metastatic breast cancer by combining nanotechnology with immunotherapy. Efstathios " Stathis " Karathanasis,   an associate professor of biomedical engineering,   is directing the novel technique--sending nanoparticles into the body to wake up " cold " tumors so they can be located and neutralized by immune cells. The team also includes researchers from Cleveland Clinic and Duke University. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2020 Category: International Medicine & Public Health Source Type: news

Gary Nabors, Ph.D. Joins Integrated BioTherapeutics Inc. as Executive...
IBT is pioneering development of the first multivalent toxoid-based vaccine against Staphylococcus aureus as well as immunotherapies for several viral diseases.(PRWeb September 14, 2020)Read the full story at https://www.prweb.com/releases/gary_nabors_ph_d_joins_integrated_biotherapeutics_inc_as_executive_vice_president_and_chief_development_officer/prweb17389568.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 14, 2020 Category: Pharmaceuticals Source Type: news

Targazyme Appoints Jim Caggiano as CEO
CARLSBAD, Calif., Sept. 11, 2020 -- (Healthcare Sales & Marketing Network) -- Targazyme Inc., a late clinical-stage biopharmaceutical company developing novel fucosyltransferase enzyme technologies and products to improve clinical efficacy, safety, and co... Biopharmaceuticals, Personnel Targazyme, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 11, 2020 Category: Pharmaceuticals Source Type: news

New immunotherapy to beat cancer
(Universit é catholique de Louvain) Sophie Lucas (University of Louvain de Duve Institute) and her team succeeded in neutralising a molecule that blocks the immune system against cancer.UCLouvain scientists discovered that this new immunotherapy increases the action of another well-known but not always effective immunotherapy, and that it makes tumour regression possible.This very promising discovery in the fight against cancer is published in the prestigious scientific journal Nature Communications. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2020 Category: Cancer & Oncology Source Type: news

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Powerful push for AI for cancer immunotherapy
(Case Western Reserve University) The companies will provide biomedical engineer Anant Madabhushi and collaborators at NYU with chest CT scan and/or digital pathology images from completed clinical trials in which their specific immunotherapy drugs were tested on lung cancer patients. Madabhushi's lab's computational-imaging tools have shown " potential to predict an individual cancer patient's response to immunotherapy, " so the collaboration can help validate research and " advance efforts to get the right treatment to the patients who will benefit the most. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

Combination immunotherapy benefits subset of patients with advanced prostate cancer
(University of Texas M. D. Anderson Cancer Center) esults from a Phase II trial led by researchers at MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with advanced prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2020 Category: Cancer & Oncology Source Type: news

UCLA study shows how interferon-gamma guides response to cancer immunotherapy
(University of California - Los Angeles Health Sciences) UCLA researchers shed light on how interferon-gamma (IFN-y) guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -- immune checkpoint blockade. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2020 Category: Cancer & Oncology Source Type: news

Immunotherapy Combo Reduces Solid Tumors in Mice
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker. (Source: The Scientist)
Source: The Scientist - September 9, 2020 Category: Science Tags: News & Opinion Source Type: news

Biopharma Leaders Unite To Stand With Science
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the un...
Source: Johnson and Johnson - September 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

New research in JNCCN sheds light on multi-organ adverse events from immunotherapy
(National Comprehensive Cancer Network) New international research in the September 2020 issue of JNCCN--Journal of the National Comprehensive Cancer Network finds immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient. Multi-organ irAEs are more likely to happen sequentially rather than simultaneously. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

'Deep dive' into biology of kidney tumors identifies markers of response to immunotherapy
(Memorial Sloan Kettering Cancer Center) An international team of investigators led by Memorial Sloan Kettering's Robert Motzer has identified biological attributes of kidney cancer tumors that correlate with better responses to immunotherapies and targeted therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2020 Category: Cancer & Oncology Source Type: news

The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy
This article will elaborate immunotherapy of sepsis, though it may not be consistent. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 3, 2020 Category: Consumer Health News Source Type: news

New connections reveal how cancer evades the immune system
(Michigan Medicine - University of Michigan) If cancer is a series of puzzles, a new study pieces together how several of those puzzles connect to form a bigger picture. A connection between three separate puzzles suggests targeting the amino acid methionine transporter in tumor cells could make immunotherapy effective against more cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 2, 2020 Category: Cancer & Oncology Source Type: news

Researchers awarded $2 million grant to study the immune system and triple negative breast cancer
(University of Tennessee Health Science Center) Liza Makowski, Ph.D., a professor in the Department of Medicine-Hematology-Oncology at the University of Tennessee Health Science Center, and Joseph F. Pierre, PhD, an assistant professor in the Department of Pediatrics-Obesity at UTHSC, have received $2.1 million from the National Cancer Institute for a five-year study to examine how the microbiome impacts the immune system and response to immunotherapy for an aggressive type of breast cancer called triple negative breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 2, 2020 Category: International Medicine & Public Health Source Type: news